Clinical trials: Epithelial Neoplasms, Malignant
Renal Cell Carcinoma
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
- Trial name
- NCT03097328
- Testing
- TAK-228
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bradley A. McGregor, MD
EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer.
- Conditions
- EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02135042
- Testing
- Bone Scan, Cisplatin, Clinical Observation
- Where
- 213 sites in United States, Australia and 6 more
- Volunteers
- 924 people
- Sponsor
- NRG Oncology
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06251973
- Testing
- AgenT-797, Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Disease, Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood.
- Conditions
- Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer
- Trial name
- NCT02414269
- Testing
- iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of the Mouth, Oropharynx Squamous Cell Carcinoma
Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell
The goal of this laboratory research study is to learn about symptoms and activity levels of patients with OPSCC that receive IMPT or TORS.
- Trial name
- NCT02663583
- Testing
- Symptom Questionnaires, Dysphagia Inventory Questionnaire, Activity Bands
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Influence of EMT on CTCs and Disease Progression in Prostate Cancer
The presence of circulating tumor cells (CTCs) in the blood of prostate cancer patients has been shown to be an important indicator of metastatic disease and poor prognosis.
- Trial name
- NCT04021394
- Testing
- CellSearch CTC platform, Parsortix CTC platform
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-clear Cell Renal Cell Cancer
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
This will be a prospective, open-label, randomized multicenter phase-II study to evaluate progression free survival (PFS) in patients with locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC) receiving…
- Trial name
- NCT00979966
- Testing
- Temsirolimus, Sunitinib
- Where
- 14 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
People with non-clear cell renal cell carcinoma may remain at high risk of cancer recurrence even after surgery has removed all visible disease.
- Trial name
- SerF-ADJ (NCT07904156)
- Testing
- Serplulimab + Fruquintinib
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
- Trial name
- NCT01034631
- Testing
- Everolimus, BNC105P
- Where
- 108 sites in United States, Australia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hoosier Cancer Research Network
Papillary Thyroid Carcinoma, Thyroid Cancer
Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals
The aim of this study is to evaluate the clinicopathological pattern and surgical outcome of papillary thyroid carcinoma (PTC) at Sohag University Hospitals.
- Trial name
- NCT07823439
- Volunteers
- 30 people
- Sponsor
- Sohag University
Small Cell Lung Cancer
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
- Trial name
- NCT06922539
- Testing
- Fenretinide
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- SciTech Development, Inc.
Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid…
- Conditions
- Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
- Trial name
- NCT03920839
- Testing
- Retifanlimab, Gemcitabine, Cisplatin
- Sponsor
- Incyte Corporation
Adenoma, Sessile Serrated Adenoma
Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions
Texture and Color Enhancement Imaging (TXI) is a newly developed image-enhancing endoscopy technology that has show potential in improving detection of colorectal lesions.
- Trial name
- NCT06515977
- Testing
- TXI (Group A), TXI followed by WLI (Group B), WLI (Group C)
- Volunteers
- 2,964 people
- Sponsor
- Changhai Hospital
Gastric Cancer, Signet Ring Cell Carcinoma
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics
Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low.
- Trial name
- NCT05985577
- Testing
- Without any intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Pituitary Adenomas, Prolactinomas
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, and select medical therapies…
- Trial name
- NCT00939523
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cedars-Sinai Medical Center
Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant Culmerciclib combined with aromatase inhibitor versus aromatase-inhibitor monotherapy in patients…
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
- Trial name
- NCT07796880
- Testing
- Culmerciclib, Aromatase Inhibitor (AI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B).
- Trial name
- PREDIX LumB (NCT02603679)
- Testing
- Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib
- Where
- 3 sites in Sweden
- Volunteers
- 181 people
- Sponsor
- Thomas Hatschek
Glioblastoma, Malignant Glioma
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
This trial assesses the quality of life in patients with high grade glioma and their caregivers using a questionnaire called the Beacon Patient Related Outcomes Quality of Life (PROQOL).
- Conditions
- Glioblastoma, Malignant Glioma, WHO Grade III Glioma
- Trial name
- NCT04630379
- Testing
- Palliative Therapy, Quality-of-Life Assessment, Supportive Care
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Renal Cell Cancer
Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size
The aim, of this study is to investigate recurrence rates in patients with T1 renal cell carcinoma (RCC) undergone partial nephrectomy (PN), radiofrequency ablation (RFA) or cryoablation (Cryo).
- Trial name
- CRYO-BO-2021 (NCT06829888)
- Volunteers
- 955 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
NEUROBLASTOMA
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
The purposes of this study are: 1. To find the highest dose of monthly intravenous Zometa that can be given with daily low doses of cyclophosphamide by mouth to children with recurrent or refractory neuroblastoma without causing…
- Trial name
- NCT00206388
- Testing
- Zolendric acid, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.